Ver el código de «Clevidipine»

==Administration==
*Type: [[Calcium channel blockers]], anti-hypertensive, dihydropyridine
*Dosage Forms: 0.5 mg/mL (50 mL, 100 mL) emulsion
*Routes of Administration: IV
*Common Trade Names: Cleviprex

==Adult Dosing==
Hypertension
*1-2 mg IV per hour
**Titration: Double dose at 90 second intervals toward blood pressure goal.
***For every 1-2 mg/hour increase should see 2-4 mm Hg reduction

==Special Populations==
===[[Drug pregnancy categories|Pregnancy Rating]]===
*C
===Lactation risk===
*Unknown

===Renal Dosing===
None

===Hepatic Dosing===
None

==Contraindications==
*Allergy to class/drug
*Allergy to soybeans, soy products, eggs, egg products
*Severe aortic stenosis

==Adverse Reactions==
===Serious===
*[[Atrial fibrillation]]
*Renal failure
*MI (<1%)
*Intestinal obstruction (<1%)
*[[Hypertriglyceridemia]] - similar to [[propofol]], formulated with 20% fat emulsion, risk of developing [[pancreatitis]]

===Common===
*Insomnia
*Nausea
*Fever
*Headache

==Pharmacology==
*Onset: 2-4 minutes
*Half-life: 1 minute
*Metabolism: hydrolysis by esterases in blood
*Excretion: Urine (63-74%); feces (7 to 22%)

==Mechanism of Action==
*Dihydropyridine CCB with arterial vasodilating activity. Inhibits calcium ion influx through L-type calcium channels. Decreases MAP and systemic vascular resistance.

==Comments==
*$1.67 per mL (25 mg/50mL or 50 mg/100 mL)


==Indications by Condition==
''The following table is automatically generated from disease/condition pages across WikEM.''

{{#ask:[[Has DrugName::Clevidipine]]
 |?Has Indication=Indication
 |?Has Dose=Dose
 |?Has Context=Context
 |?Has Route=Route
 |?Has Population=Population
 |format=table
 |headers=plain
 |mainlabel=-
 |sort=Has Indication
 |limit=50
}}

==See Also==
*[[Subarachnoid hemorrhage]]
*[[Hemorrhagic stroke]]
*[[Hypertensive emergency]]
*[[Nicardipine]]

==References==
*American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5):1122-1131. doi: 10.1097/01.AOG.0000437382.03963.88. [PubMed 24150027]
*Aronson S, Dyke CM, Stierer KA, et al, “The ECLIPSE Trials: Comparative Studies of Clevidipine to Nitroglycerin, Sodium Nitroprusside, and Nicardipine for Acute Hypertension Treatment in Cardiac Surgery Patients,” Anesth Analg, 2008, 107(4):1110-21. [PubMed 18806012]
*Cleviprex (clevidipine) [prescribing information]. Cary, NC: Chiesi USA, Inc; October 2017.
*Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061. [PubMed 26934393]
*Keating GM. Clevidipine: a review of its use for managing blood pressure in perioperative and intensive care settings. Drugs. 2014;74(16):1947-1960. [PubMed 25312594]
*Levy JH, Mancao MY, Gitter R, et al, “Clevidipine Effectively and Rapidly Controls Blood Pressure Preoperatively in Cardiac Surgery Patients: The Results of the Randomized, Placebo-Controlled Efficacy Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery-1,” Anesth Analg, 2007, 105(4):918-25. [PubMed 17898366]
*Marik PE and Varon J, “Hypertensive Crises: Challenges and Management,” Chest, 2007, 131(6); 1949-62. [PubMed 17565029]
*Peacock WF, Varon J, Garrison N, et al, “IV Clevidipine for Hypertension: Safety, Efficacy, and Transition to Oral Therapy,” Ann Emerg Med, 2007, 50(3 Suppl 1):8-9.
*Singla N, Warltier DC, Gandhi SD, et al, “Treatment of Acute Postoperative Hypertension in Cardiac Surgery Patients: An Efficacy Study of Clevidipine Assessing Its Postoperative Antihypertensive Effect in Cardiac Surgery-2 (ESCAPE-2), a Randomized, Double- Blind, Placebo-Controlled Trial,” Anesth Analg, 2008, 107(1):59-67. [PubMed 18635468]
*Varon J, “Treatment of Acute Severe Hypertension: Current and Newer Agents,” Drugs, 2008, 68(3):283-97. [PubMed 18257607]
*Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240-e327. [PubMed 23741058]
*Zhang JG, Dehal SS, Ho T, et al, “Human Cytochrome P450 Induction and Inhibition Potential of Clevidipine and Its Primary Metabolite H152/81,” Drug Metab Dispos, 2006, 34(5):734-37. [PubMed 16501008]

<references/>

[[Category:Pharmacology]] [[Category:Cardiology]]